$3.43
1.63% today
NYSE, Feb 28, 04:54 pm CET
ISIN
US44486Q1031
Symbol
HUMA
Sector
Industry

Humacyte Stock price

$3.37
-1.14 25.28% 1M
-3.29 49.40% 6M
-1.68 33.27% YTD
-1.16 25.61% 1Y
-2.66 44.11% 3Y
-8.83 72.38% 5Y
-8.83 72.38% 10Y
NYSE, Closing price Thu, Feb 27 2025
-0.06 1.75%
ISIN
US44486Q1031
Symbol
HUMA
Sector
Industry

Key metrics

Market capitalization $433.61m
Enterprise Value $430.16m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-112.49m
Free Cash Flow (TTM) Free Cash Flow $-92.26m
Cash position $20.72m
EPS (TTM) EPS $-1.34
P/E forward negative
Short interest 24.11%
Show more

Is Humacyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Humacyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Humacyte forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Humacyte forecast:

Buy
86%
Hold
14%

Financial data from Humacyte

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 8.80 8.80
17% 17%
-
-8.80 -8.80
17% 17%
-
- Selling and Administrative Expenses 6.76 6.76
18% 18%
-
- Research and Development Expense 88 88
24% 24%
-
-104 -104
19% 19%
-
- Depreciation and Amortization 8.80 8.80
17% 17%
-
EBIT (Operating Income) EBIT -112 -112
19% 19%
-
Net Profit -153 -153
71% 71%
-

In millions USD.

Don't miss a Thing! We will send you all news about Humacyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Humacyte Stock News

Neutral
GlobeNewsWire
about 19 hours ago
DURHAM, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D.
Neutral
GlobeNewsWire
one day ago
– Patent provides coverage into 2040 for key aspects of the bioreactor manufacturing system – – Symvess, the acellular tissue engineered vessel, is manufactured in this patented system – DURHAM, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial sca...
Neutral
GlobeNewsWire
2 days ago
– The FDA has authorized Humacyte to release commercial shipments – – Positive responses from surgeons and trauma centers to initial sales and marketing outreach – - 21 hospitals have already initiated the Value Analysis Committee (VAC) approval process – DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing u...
More Humacyte News

Company Profile

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Head office United States
CEO Laura Niklason
Employees 183
Founded 2004
Website humacyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today